Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause

NCT05325775 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Post-menopausal Vasomotor Symptoms

Interventions

DRUG: ACER-801 50 mg BID
DRUG: ACER-801 100 mg BID
DRUG: ACER-801 200 mg BID
DRUG: Placebo

Sponsor

Acer Therapeutics Inc.